Augustine Therapeutics

Belgium
Leuven, Flanders, Belgium, 3001

Company profile

Augustine Therapeutics company profile

Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2019-03-01, Month

Headquarters

Postal code
3001
Country code
BE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$106.8M
Last funding
Series A / $83.9M / 2025-03-24
Last equity funding
Series A / $83.9M
Investors
11
Lead investors
4
Founders
3
Articles
42

Founders and investors

Founders

Bart De StrooperJoris De WitLudo Van den Bosh

Lead investors

Asabys PartnersJeito CapitalNovo HoldingsV-Bio Ventures

Investors

AdBio partnersAsabys PartnersEli LillyJeito CapitalNovo Holdings